Next, we stained pathological sections of NPC patients (Table S1, n=15) treated with PD-L1-targeted therapy (positive for PD-L1 as described in the medical records) with anti-CD38 antibody (Figure S8) and found positive staining in 86.7% of patients (13/15). This evidence concerns the gene CD38 and nasopharyngeal carcinoma.